Topical dorzolamide 2%/timolol 0.5%: A review of its use in the treatment of open-angle glaucoma

Drugs and Aging

Volumn 17, Issue 6, 2000, Pages 477-496

  Ormrod, D ^a   McClellan, K ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Glaucoma; Ocular hypertension; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Timolol dorzolamide

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; PILOCARPINE; TIMOLOL;

ALLERGIC REACTION; BLINDNESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG MIXTURE; DRUG TOLERABILITY; EYE BLOOD FLOW; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MONOTHERAPY; NAUSEA; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

EID: 0034489369     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200017060-00005     Document Type: Review

References (62)

1. Epidemiology of chronic open-angle glaucoma
2. Dorzolamide: A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension
3. The global impact of glaucoma
4. Number of people with glaucoma worldwide
5. Pharmacological therapy for glaucoma: A review
6. Identification of a gene that causes primary open angle glaucoma
7. Genetic heterogeneity of primary open angle glaucoma and ocular hypertension: Linkage to GLC1A associated with an increased risk of severe glaucomatous optic neuropathy
8. Prospects for genetic interventions in primary open-angle glaucoma
9. Timolol: A review of its therapeutic efficacy in the topical treatment of glaucoma
10. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox
11. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension
12. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension
13. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure
14. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure
15. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxotol
16. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors
17. Topical ophthalmic beta blockers. A comparative review
18. The mechanism of timolol in lowering intraocutar pressure in the normal eye
19. Effect of timolol therapy on outflow facility
20. Timolol and facility of outflow
21. Timolol inhibits adenytate cyctase activity in the iris-ciliary body and trabecular meshwork of the eye and blocks activation of the enzyme by salbutamol
22. The treatment of glaucoma: Role of β-blocking agents
23. Longterm timolol therapy
24. Long-term drift and continued efficacy after multiyear timolol therapy
25. Timolol: A new drag for the management of chronic simple glaucoma
26. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor
27. Dorzolamide effect on ocular blood flow
28. Dorzolamide, visual function and acular hemodynamics in normal-tension glaucoma
29. Binding of dorzolamide and its metabolite, N-deethytated dorzolamide, to human erythrocytes in vitro
30. Effects of dorzolamide on retinal and retrobulbar hemodynamics
31. A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients
32. Effects of dorzolamide hydrochloride 2% on the retinal circulation
33. Ophthalmic topical beta blockers: Review of ocular and systemic adverse effects
34. Comparison of the effects of timolol and other adrenergic agents on intraocutar pressure in the rabbit
35. The disposition of timolol in man
36. Physiological disposition and metabolism of timolol in man and laboratory animals
37. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide
38. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor
39. Pharmacokinetics of topically applied ophthalmic drugs
40. Nonlinear dorzolamide pharmacokinetics in rats: Concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction
41. In vitro metabolism of dorzolamide, a novel potent carbolnic anhydrase inhibitor, in rat liver microsomes
42. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor
43. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide
44. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide
45. The efficacy and safety of the dorzolamide-timotol combination versus the concomitant administration of its components
46. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: A clinical equivalence study
47. Dorzolamide
48. The dorzolamide/timolol combination versus timolol plus pilocarpine: Patient preference and impact on daily life
49. Efficacy and adverse effects of medications used in the treatment of glaucoma
50. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol
51. Central corneal endothelial cell changes over a 10 year period
52. Irreversible corneal decompensation in patients treated with topical dorzolamide
53. Irreversible corneal decompensation in patients treated with topical dorzolamide
54. The analysis of plasma kinetics and β-receptor binding and -blocking activity of timolol following its small intravenous dose
55. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients
56. Severe bradycardia due to interaction of timolol eye drops and verapamil
57. Timolol eye drops and verapamil - A dangerous combination
58. The national survey of trabeculectomy. I. Sample and methods
59. Dorzolamide versus pilocarpine as adjunctive therapies to timolol a comparison of patient preference and impact on daily life